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INTRODUCTION 
Type 2 diabetes mellitus is the most common endocrinopathy 
commonly encountered in clinical practice. It is a group of diseases 
characterized by absolute or relative lack of insulin ultimately resulting in 
increased blood glucose or simply hyperglycemia. 
Cardiovascular disease is frequently encountered in patients with type 
2 diabetes mellitus. In fact, it contributes to significant morbidity and 
mortality in such patients upto the tune of 80 %. The economic burden in 
managing type 2 diabetic patients with co existent cardiovascular disease is 
very high. Various cardiovascular manifestations can occur in patients with 
type 2 diabetics notably coronary artery disease. Also, on a comparative 
viewpoint patients with diabetes have increased risk for development and 
also of dying from coronary artery disease than non diabetics. In addition, 
they have increased risk for developing  macrovascular complications like 
peripheral vascular disease and stroke besides other microvascular 
complications. 
 Sustained hyperglycemia can influence the development and 
progression of atherosclerosis. This has been attributed to vascular 
perturbations linked to diabetes which include – endothelial dysfunction, 
effects of advanced glycation end products , effects of circulating free fatty 
acids and increased systemic inflammation. Besides, hypertension and 
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dyslipidemia influence and accelerate the progression of atherosclerosis in 
patients with type 2 diabetes mellitus. 
Diabetes is an independent risk factor for heart failure which can be 
both systolic and/ or diastolic heart failure; and patients have the worst 
outcomes once heart failure has developed. 
Diabetics and non diabetics- can both have various common features 
such as ischemic heart disease, hypertension, left ventricular hypertrophy, 
atrial fibrillation and valvular disease; however there is increased myocardial 
vulnerability to the effects of the aforementioned factors which may act in a 
synergistic fashion to increase risk for morbidity and mortality in patients 
with diabetes mellitus. 
Diabetic cardiomyopathy is not an old concept, it is fairly new and a 
distinct entity. It was in 1972 that for the first time in the history of medicine 
fascinating observations were made. 4 patients were found to have diabetes 
and heart failure without any evidence of systemic hypertension or coronary 
artery disease. The dissection of the heart revealed startling facts. There was 
evidence of LV hypertrophy and fibrosis without atheroma of coronary blood 
vessels or another substrate responsible for the above mentioned finding. This 
clinical entity was baptized with the terminology “Diabetic 
Cardiomyopathy”. 
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Thus, the condition is defined as myocardial dysfunction in patients 
with diabetes mellitus in the absence of hypertension, coronary artery disease 
or other known cardiac disease. This concept was brought to light through 
various experimental, epidemiological, pathological and clinical studies. The 
studies highlighted the presence of various myocardial changes - both 
structural and functional in patients with diabetes with no other co morbid 
illnesses. These include myocardial damage, hypertrophy of left ventricle, 
myocardial small vessel changes, cardiac autonomic neuropathy, etc. 
The etiology and pathogenic mechanisms implicated in diabetes are 
multifactorial. Sustained hyperglycemia has been found to cause disturbances 
in ionic channels like sodium – potassium ionic channel, generation of 
reactive oxygen species, deposition of advanced glycation end products, 
inflammatory reaction, myocardial fibrosis etc., all of which play a crucial 
role in the genesis and maintainence of diabetic cardiomyopathy. 
With regard to heart failure, in diabetics without any co morbidities 
diastolic dysfunction dominates the early course with relatively preserved 
ejection fraction before they proceed to develop systolic dysfunction by 
which time patient has overt symptoms of heart failure and various other 
complications of diabetes both macrovascular like stroke, peripheral vascular 
disease and microvascular like retinopathy, neuropathy and nephropathy. The 
development of systolic dysfunction portends a poor prognosis. 
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Diastolic dysfunction which is an early feature in diabetes can be 
assessed using non invasive methods like echocardiography which uses 
parameters like transmitral inflow velocity, tissue Doppler lateral annulus 
velocity, deceleration time etc. These parameters show the presence of 
impaired relaxation time with normal systolic function early in the course of 
diabetes. 
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AIMS AND OBJECTIVES 
 
1. To study the correlation between HbA1C levels with grades of 
diastolic dysfunction in asymptomatic type 2 diabetic individuals. 
 
2. To study the prevalence of diastolic dysfunction in asymptomatic 
type 2 diabetic individuals in relation to duration of diabetes, 
differences in sex. 
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REVIEW OF LITERATURE 
HISTORICAL REVIEW 
The term “diabetes” was used first by Apollonius of Memphis around 
the year 230 B.C. which in Greek means “to pass through”. The words 
describe a siphon that described polyuria. 
In India, at around the same time, physicians observed that the urine 
from people with diabetes attracted flies and ants. They also noted that such 
patients had extreme thirst and foul smelling breath. They named the 
condition – ‘madhumeha’ or ‘honey urine’ ¹. It was only later in the 5th 
century that two renowned physicians namely Sushruta and Charaka 
differentiated between the two types of diabetes mellitus. They noticed that 
lean individuals who developed diabetes did so at an earlier age rather than 
heavier individuals who developed diabetes at a later age.   
Aulus Cornelius Celsus gave the first complete clinical description of 
diabetes in his exemplary work comprising of eight volumes entitled – De 
medicine ². 
Aretaeus of Cappadocia was the first to distinguish between diabetes 
mellitus and diabetes insipidus ³.Together with Galen, who was a roman 
physician, he observed that the condition was a rare one. In fact, Galen 
mentioned that he had noticed only two such cases in his entire career! 
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Frederick Banting, an orthopaedic surgeon and Charles Best, a 
physiology student finally identified the substance in the year 1920 whose 
deficiency was postulated to be responsible for the development of diabetes⁴ 
for which they were awarded the noble prize. Banting initially named the 
antidiabetic substance as “isletin” and later, MacLeod christened it as  
“insulin” as we know it today ⁵. The discovery of insulin was revolutionary in 
the field of medicine and over the years several purification methods were 
used and newer insulin formulations have been tried. 
INSULIN AND GLUCOSE METABOLISM: 
The effects of insulin on glucose metabolism is myriad. Insulin and 
various other “counter regulatory hormones” as we call them serve to 
maintain normoglycemia. The arterial glucose values averages around 90 
mg/dl with a maximum of 165 mg/dl after ingestion of a meal ⁶and remains 
above 55 mg/dl even after exercise⁷ or a moderate fast⁸.  A decrease in even 
20 mg/dl (90 – 70mg/dl) will suppress the release of insulin and stimulate the 
production of counter regulatory hormones like cortisol, growth hormone, 
glucagon and catecholamines which ultimately serve to maintain a state of 
euglycemia⁹. 
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Glucose is considered to be obligate fuel for the brain and only after a 
considerable period of fasting ketone bodies are  used by the brain to a 
significant extent ¹⁰. 
ROLE OF INSULIN : 
Insulin regulates the metabolism of glucose by both direct and indirect 
mechanisms. The effects are as described below: 
• Suppression of release of glucose from kidney and liver¹¹ 
• Increased glucose uptake in muscle and adipose tissue¹² 
• Suppression of hormone sensitive lipase resulting in inhibition of 
release of free fatty acids and enhancing their clearance¹³ 
• Promotes glycogen accumulation by inhibiting glucose 6 phosphatase 
and phosphorylase and stimulating glycogen synthase¹⁴ 
Chief regulator of insulin secretion is plasma glucose. Increased 
glucose such as after a meal stimulates insulin secretion which tends to lower 
the sugar values. On the other hand, during fasting there is a surge of counter 
regulatory hormones which tends to increase blood sugar values. Also, after 
consumption of a meal, there is release of certain intestinal factors called “ 
incretins ” which augment insulin secretion. 
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ROLE OF GLUCAGON: 
Glucagon is secreted by the alpha cells of the pancreas and the main 
factors which influence its secretion are insulin and glucose. Its secretion is 
inhibited by increased blood sugar levels and stimulated by decreased blood 
sugar levels. It acts mainly on the hepatic cells and its immediate action is to 
increase blood glucose levels mainly by a process called glycogenolysis. This 
means that the stored glucose in the hepatic cells is released at the time of 
fasting. Only later is the process of gluconeogenesis activated where glucose 
is synthesized from many sources like -  amino acids, lactate etc., for the 
purpose of energy generation. 
ROLE OF CATECHOLAMINES: 
Catecholamines mainly act through beta adrenergic receptors to 
increase blood glucose levels – i.e., the net effect is hyperglycemia and this 
take place in response to stress and hypoglycaemia. In the kidney, they 
stimulate gluconeogenesis and in skeletal muscles they stimulate 
glycogenolysis resulting in formation of lactate, a chief precursor for 
gluconeogenesis. In a similar fashion they stimulate lipolysis in adipose 
tissue resulting in release of FFA and also glycerol , again key precursors for 
gluconeogenesis. 
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ROLE OF GROWTH HORMONE AND CORTISOL: 
The actions of the above two hormones takes time to become evident. 
The hormones are antagonistic to insulin – meaning that they enhance 
gluconeogenesis and reduce glucose transport. Cortisol is also found to 
impair insulin secretion. That is why treatment with immunosuppressive 
glucocorticoids cause glucose intolerance over a period of time because they 
result in insulin resistance and prevent an appropriate rise in compensatory 
insulin secretion.    
ROLE OF FREE FATTY ACIDS: 
Except brain, blood cells and the renal medulla, most tissues in our 
body use free fatty acids as their metabolic fuel. Their presence has numerous 
metabolic consequences. They are regulated by insulin ( decrease the levels 
of FFA ), growth hormone and sympathetic nervous system ( increase  FFA 
levels ) and hyperglycemia. 
Therefore, understanding the various hormones involved in glucose 
metabolism is vital. 
Diabetes mellitus is thus a disorder of glucose metabolism which 
results from either absolute or relative insulin deficiency resulting in 
hyperglycemia with a range of effects on various organ systems in the body. 
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The mechanisms may be genetic, acquired or environmental. 
Diabetes mellitus is classified as:¹⁵ 
(A) Type 1 DM 
(B) Type 2 DM 
(C) Gestational DM and 
(D) Other types of DM which include those due to genetic defects, 
drugs like corticosteroids, infections, etc.  
DIAGNOSING DM: 
A patient can be suspected to have diabetes mellitus if he / she presents 
with the classical clinical features of increased thirst, increased urination, 
recent weight loss and has a random blood glucose value of ≥ 200 mg/dl. 
Various other criteria have been proposed based on the risk of 
developing microvascular complications like retinopathy and observed 
association between glucose levels. 
A fasting plasma glucose value of ≥ 126 mg/dl, glycated haemoglobin 
of ≥ 6 .5% and the two hour post  oral glucose tolerance test value of ≥ 200 
mg/dl¹⁶  are associated with increased risk of developing microvascular 
complications like retinopathy, nephropathy and neuropathy. 
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Of the said criteria, glycated haemoglobin deserves special mention. 
Initially, the use of glycated haemoglobin was not approved as there were no 
uniformity in assays worldwide¹⁷. However in June 2009, American Diabetes 
Association recommended that glycated haemoglobin  can be used with 
accuracy to diagnose diabetes in both children and in adults but the same 
could not be used in pregnant women. 
 A HbA1c value of ≥ 6.5 % was used as cut off to make a diagnosis of 
diabetes mellitus and studies have shown that HbA1c level is an excellent 
marker for cardiovascular morbidity and mortality , and is gold standard in 
monitoring therapy¹⁸. 
ADA criteria to define population at high risk for diabetes: 
Patient’s age more than 45 years. 
Patient’s age less than 45 years with the following: 
a. Obesity 
b. Family history with diabetes mellitus (parents or siblings) 
c. Previous history of GDM or delivered a baby weighing more than 4 
kgs. 
d. Presence of hypertension. 
e. Presence of hyperlipidemia. 
f. Previous evidence of IGT or IFG. 
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g. Member of a minority population. 
h. History of vascular disease 
i. Habitual physical inactivity 
j. Polycystic ovarian disease. 
DIABETES AND THE HEART: 
Cardiovascular disease is the principal cause of death in patients with 
type 2 diabetes mellitus. Diabetics are at increased risk of myocardial 
infarction compared with the general population¹⁹. To make matters worse, 
even if patients with diabetes develop coronary artery disease, their survival 
outcomes are poor and not satisfactory compared to non diabetics. 
Patients often have a ‘ silent myocardial infarction ’ in the setting of 
diabetes ²⁰ indicating that such patients are detected to have myocardial 
ischemia (due to coronary atherosclerosis) only  on investigations like the 
electrocardiograph and echocardiography as they don’t have any symptoms. 
This is presumably because of cardiac autonomic neuropathy which affects 
both sympathetic and parasympathetic systems. 
Such patients are also likely to die of myocardial infarction even before 
they reach the hospital than non diabetics²¹. This can be due to probable co 
existing diabetic heart muscle disease which results in myocardial 
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contractility and this occurs independent of coronary artery disease. This has 
been termed diabetic cardiomyopathy which will be described in detail later. 
This concept was derived from a landmark trial conducted during the 
1970’s. 73 patients with idiopathic form of primary myocardial disease were 
chosen out of which only 16 patients were found to have diabetes mellitus. 
They were compared to matched patients who did not have cardiomyopathy. 
57 of them were excluded as they had history of chronic alcoholism and other 
causes associated with cardiomyopathy. The chosen 16 were diagnosed with 
diabetes earlier itself, even before the patients could enter into the study. The 
patients were subjected to detailed physical examination and investigations 
and the results were tabulated. 
Autopsy conducted in 3 of 4 dead diabetic persons showed intramural 
small vessel changes in the absence of any large vessel changes. On the other 
hand, autopsy conducted in 28 non diabetic individuals showed only one 
person having small vessel changes and that patient was found to have PAN. 
Thus, it was concluded from the study that the idiopathic 
cardiomyopathic changes in diabetic patients with poorly controlled blood 
could possibly be due to intramural small vessel changes.²² 
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RISK FACTORS FOR CARDIOVASCULAR DISEASES IN TYPE 2 
DIABETICS:  
In addition to diabetes mellitus, cardiovascular disease in diabetics can 
also be accelerated by co existing risk factors which can be divided into 
modifiable and non modifiable risk factors. 
Non modifiable risk factors are: 
(A) Old Age 
(B) Male Gender 
(C)  Type A personality 
(D) Familial hypercholesterolemia 
(E) Hyperhomocystenemia 
Modifiable risk factors are: 
(A) Obesity 
(B) Sedentary lifestyle 
(C) Smoking 
(D) Excessive alcohol consumption 
(E) Consumption of diet lacking in vegetables or antioxidants 
(F) Increased consumption of saturated  fat, red meat etc. 
The aforementioned factors play a synergestic role in increasing 
cardiovascular mortality and morbidity in patients with diabetes mellitus. 
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Type 2 diabetes is now considered to be a vascular disorder – 
otherwise “ vasculopathy”. Various vascular disturbances are known to occur 
in diabetics with a wide spectrum of consequences including predisposition 
and promotion of thrombosis and vasospasm. 
Cardiovascular disease risk in diabetics was studied in various trials. 
The WHO multinational trial ²³  which enrolled about 3,583 patients 
established that neither the degree of hyperglycemia or the duration of 
diabetes was related to the amount of cardiovascular deaths. The Framingham 
study ²⁴ which enrolled 239 subjects also did not establish any relationship 
between hyperglycemia and incidence of cardiovascular deaths. A similar 
outcome was derived in the Whitehall study ²⁵ which enrolled 178 subjects. 
However, the Wisconsin Epidemiological study of Diabetic 
Retinopathy ²⁶ which enrolled around 10,135  diabetic subjects revealed that 
a 1% decrease in HbA1c level predicted a 10% fall in CVD events but 50% 
reduction in occurrence and progression  of retinopathy without adjustment 
for other CVD risk factors.  
Therefore, optimal glucose control is necessary to retard the 
progression of myocardial disease. 
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Mechanisms of diabetic cardiomyopathy: 
The mechanisms proposed to cause diabetic cardiomyopathy can be 
discussed under the following headings: 
(a) Metabolic disturbances 
(b) Small vessel disease 
(c) Myocardial fibrosis 
(d) Insulin resistance 
(e) Autonomic dysfunction 
Metabolic disturbances in diabetics: 
1. Disturbances in substrate supply and utilization -  
Diabetic individuals have a defect in stimulation of glycolysis and 
oxidation of glucose²⁷ primarily because of the following reasons: 
 Slow rate of transport of glucose into myocardium basically due 
to depletion in the number of glucose transporters like GLUT 1 
and GLUT 4 resulting in reduced myocardial glucose supply 
and its utilization²⁸. 
 High levels of free fatty acid – contributes to inhibitory effect of 
fatty acid oxidation on pyruvate dehydrogenase complex, a 
crucial enzyme in glucose metabolism²⁹. 
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The above two mechanisms have an influence on the diabetic 
myocardium resulting in reduced myocardial ATP availability, particularly in 
type 2 diabetic individuals. 
Recent studies also indicate that as a consequence of oxidative stress 
resulting from deranged glucose metabolism, there is alteration in the 
function of the so called “cardiac progenitor cells”. This results in a defective 
cardiac progenitor cell growth and consequent myocyte dysfunction. The 
above derangements lead ultimately to myocardial aging/ apoptosis and heart 
failure ³⁰. 
Substrate metabolism affecting the myocardial contractility was clearly 
demonstrated in genetically determined mice. This contractile dysfunction 
was clearly evident in the form of increases LV end diastolic pressure, 
reduced LV pressure and cardiac output. 
2. Free fatty acid metabolism: 
There is increased free fatty acid levels in type 2 diabetic individuals. This 
is a result of enhanced lipolysis of adipose tissue and reduced levels of a key 
molecule called carnitine which is important in the clearance of free fatty 
acids. 
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The above problems lead to: 
 Abnormally high requirements of oxygen in the metabolism of 
free fatty acids. 
 Intracellular accumulation of potentially toxic substances 
 Impairment of glucose oxidation 
These ultimately result in reduced myocardial performance and 
morphological changes which tends to become better with metabolic 
improvement³¹. 
Role of carnitine deficiency was found in streptozotocin induce 
diabetic rats without any evidence of coronary occlusion and normal 
cholesterol levels which correlated well with decreased serum and 
myocardial carnitine levels and also abnormally visualized mitochondria³². 
3. Disturbances in calcium homeostasis regulation: 
The accumulation of toxic molecules, free radicals and abnormal lipid 
molecules in cell membrane result in alteration in key proteins - both 
regulatory and contractile, calcium ATPase and sodium  -  calcium exchanger 
function. 
There is altered calcium sensitivity of the so called ‘regulatory 
proteins’ involved in myocardial actin – myosin regulation. Impaired left 
ventricular function in such a situation can be attributed to: 
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 Diminished calcium sensitivity³³ 
 Decreased cardiac pump protein 
 Decreased sarcoplasmic reticulum calcium ATPase³⁴ 
The above factors result in both - abnormal systolic and abnormal 
diastolic dysfunction. 
In diabetic without a known cause of myocardial dysfunction or 
cardiac disease the disturbances of LV function primarily reflect diastolic 
dysfunction which can be attributed positively to factors such as interstitial 
collagen deposition which can be reversed with insulin therapy. 
4. Disordered copper metabolism: 
Serum copper levels are found to be elevated in patients with type  
2 diabetes mellitus particularly in those with microvascular complications 
like retinopathy and co existing hypertension³⁵. The copper binding 
properties of ceruloplasmin are lost and this leads to increased deposition of 
copper in extracellular matrix³⁶  which activates the oxidation reduction 
system. As a result of the activation, there is increased production of free 
radicals which results in oxidative stress and myocardial fibrosis³⁷.  
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CORRELATION OF THE VARIOUS CHANGES SEEN IN 
METABOLISM OF SUBSTRATE WITH LV DYSFUNCTION: 
In an experimental study where diabetes was induced with 
streptozotocin the following changes were consistently noted. 
 First, time to peak tension and time to half relaxation were prolonged, 
 Second, peak rate of rise of tension and fall of tension was depressed, 
 Third, there existed an inverse correlation between HbA1C levels and 
peak late filling velocity in type 2 diabetics whereas on the other hand 
a direct correlation existed between diastolic velocity time integral and 
age, duration of diabetes and serum glycated haemoglobin³⁸. 
Therefore, it is apt to say that the cardiac dysfunction depends on the 
following factors: 
 Duration of diabetes – longer the duration, more the cardiac 
dysfunction. 
 Poor glycemic control 
 Low serum IGF -1 levels³⁹ 
 High glycated haemoglobin levels 
Response to therapy: 
In an experimental study involving mice it was noted that insulin 
therapy reversed some of the key morphological changes which include: 
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• Increase in LV systolic pressure 
• Increase in LV developed pressure and overall LV chamber stiffness 
constant 
• Decrease in the LV end diastolic pressure 
• Decrease in size of LV cavity/wall volume and end diastolic volume 
• Decrease in LV relaxation time constant⁴⁰ 
Therefore early insulin therapy may prove very beneficial. 
2. Myocardial fibrosis 
Studies have revealed that there is increased prevalence of myocyte 
necrosis in diabetics particularly in those with co existing hypertension⁴¹. The 
myocyte necrosis results in a variety of changes like widening of extracellular 
compartments and increased collagen deposition either in a diffuse or 
scattered manner⁴². This results from replacement fibrosis consequent to 
myocyte necrosis and connective tissue proliferation⁴³. 
Sustained hyperglycemia results in: 
• Glycosylation of amino acid lysine residues results in impaired 
collagen degradation  
• Production of reactive oxygen species resulting in oxidative stress 
which in turn affects the gene expression and alters signal transducing 
capacity leading to activation of apoptosis or programmed cell death. 
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An interesting fact is that there is glycosylation of p53 molecule also 
resulting in an increase in angiotensin II synthesis – culminating in p53 
phosphorylation and increased expression of the molecule Bax leading to 
myocyte apoptosis. 
It was also inferred from experimental data that an active endothelin 
system  in  type 2 diabetic plays a crucial role in myocardial fibrosis. This 
results from alterations in receptors for endothelin 1 resulting in an important 
effect that is focal fibrous scarring⁴⁴. 
A crucial substance regulating myocardial fibrosis in diabetics is IGF 1 
levels. This substance is found to reduce both angiotensin II and apoptosis. 
The observation was supported by the fact that treatment with insulin usually 
reverses the various contractile disturbances noticed in type 2 diabetics.  
Role of IGF 1: 
• IGF increases myocardial contractility⁴⁵ - there is accumulation of 
intracellular calcium and also there is increased sensitivity of the 
cardiac myocytes to circulating calcium 
• It acts in a synergistic fashion with angiotensin II in promoting cellular 
development⁴⁶ – this leads to cardiac hypertrophy even when BP is in 
the normal range. 
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IGF 1 is present in cardiac cells and its expression is increased by 
increased peripheral vascular resistance, increased myocardial wall stress and 
decreased insulin concentration. 
Role of TGF β: 
Transforming growth factor β₁ produce chiefly by cardiac  fibroblasts 
potentiates the effects of angiotensin II⁴⁷. It is a well known fact that the 
effects of TGF β₁  are pleiotropic. TGF β₁ also increases formation of fibrous 
tissue and is involved in upregulation of collagen expression particularly 
during tissue repair. The TGF β₁ receptor II is found to be increased in the 
ventricle in experimental studies involving OLETF.  
CORRELATION OF THE CHANGES WITH LV DYSFUNCTION: 
In diabetic individuals cardiac dysfunction -both systolic and diastolic 
has different pathophysiologic mechanisms. 
The systolic dysfunction observed may be attributed more to the 
degree of myocyte injury and myocyte loss. On the other hand, in contrast, 
the diastolic dysfunction noticed may be the consequence of both myocardial 
injury and accumulation of interstitial collagen. A fair relationship exists 
between myocardial fibrosis, metabolic disturbances and diastolic 
dysfunction. This can be superimposed on the stages of diastolic dysfunction 
as follows: 
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STAGES 
DESCRIPTION OF DIASTOLIC 
DYSFUNCTION 
CORRELATION 
WITH 
MYOCARDIAL 
CHANGES 
STAGE 1 
(MILD) 
Impaired myocardial relaxation – 
both myocardial and mitral inflow 
E/A < 1 –impaired relaxation mitral 
inflow pattern 
Metabolic disturbance 
is more pronounced 
than myocardial 
fibrosis 
STAGE 2 
(MODERATE) 
Myocardial E/A < 1 
Mitral inflow E/A>1 
Pseudonormal pattern of flow 
Moderate amount of 
myocardial fibrosis 
and there is increased 
LA pressure 
STAGE 3 
(SEVERE) 
Myocardial E/A <1 
Mitral inflow E/A > 1.5 
Restricted mitral inflow pattern 
Severe amount of 
myocardial fibrosis 
and theres is also 
markedly increased  
LA pressure. 
  
Therefore it is clearly evident from the above chart that the severity of 
diastolic dysfunction correlates with changes noted both in substrate 
metabolism and  myocardial fibrosis. This highlights the fact that early 
screening of type 2 diabetics with non invasive methods like 
echocardiography may reveal subtle diastolic dysfunction, a finding which 
can prompt initiation of therapy and retard the progression of myocardial 
dysfunction in type 2 diabetics. 
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Small vessel changes: 
These can be divided into structural and functional: 
A. Structural 
In type 2 diabetes mellitus, there is microangiopathy invoving the 
arterioles, capillaries and venules. These changes include: 
• Basement membrane thickening 
• Arteriolar thickening 
• Capillary microaneurysms 
• Decreased capillary density which can be due to periarteriolar fibrosis 
and focal proliferation of subendothelial space and fibrosis. 
These changes result in injury to myocardial cells and interstitial fibrosis⁴⁸. 
B. Functional : The changes include:- 
• Impaired coronary vascular reserve and this is a very crucial and 
change 
• Abnormal endothelium dependent vasodilatation 
The above structural and functional changes result in diabetic 
cardiomyopathy probably as a consequence of myocardial ischemia due to 
increases myocardial demand occurring the setting of microvascular spasm. 
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Apart from the above said changes, the other changes in vascular system 
include: 
Changes in endothelium: 
• Increased NK- ĸβ activation 
• Decreased production of nitric oxide 
• Decreased bioavailabilty of prostacyclin 
• Increased activity of endothelin 1 
• Increased activity of angiotensin II 
• Increased activity of cyclooygenase 2 
• Increased activity of thromboxane A₂ activity 
• Increased production of reactive oxygen species 
• Increased products of lipoid production 
• Decreased endothelium dependent relaxation 
• Increased expression of receptor for advanced gycation end products 
Changes in vascular smooth musculature and matrix: 
• Increased proliferation and migration into the intima 
• Altered matrix composition and reduced degradation 
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Inflammatory changes: 
• Increased levels of IL 1β, IL 6, CD36 and MCP 1 
• Increased expression of ICAMs, VCAMs and selectins 
• Increased advanced glycation end products and AGE /RAGE 
interactions 
• Increased activity of protein kinase C 
Changes in platelets: 
• Increased metabolism of arachidonic acid 
• Increased synthesis of thromboxane A₂ , a potent vasoconstrictor 
• Decreased levels of vasodilators like nitric oxide and prostacyclin and 
antioxidants. 
• Reduced fluidity of platelet membrane 
• Altered homeostasis of calcium and magnesium 
• Increased turnover of platelets and 
• Increased formation of platelet microparticles 
The aforementioned changes seen both in small and large vessels were 
demonstrated in experimental animals. Animal studies also revealed that 
angiogenic respone which should occur as a result of cardiac ischemia 
consuequent to small vessel changes is blunted due to markedly redu ed 
vascular endothelial growth factor and its receptors. 
29 
 
In conclusion, metabolic derangements in diabetes mellitus which 
occur early in the course initiate injury to the vessels by various mechanisms 
which over a period of time progress to cause: 
a. Abnormal vascular sensitivity to various ligands 
b. Decreased autonomic function 
c. Increased stiffness of the arteriolar wall 
d. Abnormalities of proteins controlling ion movements 
         These ultimately are responsible for causing  ‘diabetic cardiomyopathy’ 
and this correlates well with HbA1c levels and reduces with therapy⁴⁹. 
Cardiac autonomic neuropathy: 
The concept of cardiac autonomic neuropathy in diabetes mellitus is 
also implicated in diabetic cardiomyopathy. It is detected by changes in heart 
rate variability in response to  exercise⁵⁰ or dipyridamole stress⁵¹ and an 
alteration in the balance between sympathetic and parasympathetic balance. 
Sympathetic denervation is a vital feature of  cardiac autonomic 
neuropathy in type 2 DM . A study performed using radiocontrast material  - 
¹²³I – MIBG showed that there was global decrease of myocardial uptake  of 
¹²³I – MIBG in diabetics⁵²  indicating cardiac sympathetic denervation. The 
posterior part of myocardium is predominantly involved than lateral and 
apical regions indicating the presence of regional heterogeneity in cardiac 
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sympathetic denervation⁵³. Also the study revealed another spectacular fact. 
The maximal denervation occurred more distally⁵⁴ than proximally and this 
was associated with proximal ventricular islands of hyperinnervation⁵⁵. As a 
result there are many unstable electrical and vascular regions in the 
myocardium. 
The above findings were known to occur with increased severity in 
type 2 diabetes mellitus. Various parameters like relative tracer retention was 
reduced more in myocardial apical, lateral and inferior areas and also 
measurements of absolute tracer retention index also showed a drastic 
reduction in distal areas as compared with proximal areas⁵⁶ . 
On myocardial infusion of adenosine, it was observed that LV 
myocardial blood flow and also coronary flow reserve were decreased to a 
significant extent in patients with neuropathy than non neuropathic diabetic 
individuals⁵⁷. 
β adrenergic receptor density and cardiac norepinephrine content were 
found to be increased to a great extent particularly in short term diabetics⁵⁸. 
This led to the idea that cardiac β adrenergic activity is enhanced by changes 
in cardiac sympathetic activity. A note should also be made of the increased 
bradykinin induced release of norepinephrine which is greater in diabetic 
individuals⁵⁹.  
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With regard to the parasympathetic system, heart rate variability during 
deep breathing can be demonstrated and with respect to sympathetic system 
abnormalities, alterations in both systolic and diastolic function are noted. 
There is decrease in the elastic properties and enhanced peripheral vascular 
resistance in diabetics due to augmentation of sympathetic tone⁶⁰. 
Cardiac autonomic neuropathy influences LV function in three 
important ways: 
• Disturbs the myocardial contractile response to stress ,a key feature. 
• Systolic dysfunction which was found to be more evident when the 
patient was subjected to exercise. 
• Diastolic dysfunction which was found to be more evident with patient 
at rest⁶¹. 
Thus, in summary, it was noted that cardiac autonomic neuropathy  
involves both sympathetic and parasympathetic components and in 
implicated in causing both systolic and diastolic dysfunction in individuals 
with type 2 diabetes mellitus. There is increased  predisposition to sudden 
cardiac death in diabetics with CAN⁶². 
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Insulin resistance: 
Insulin resistance together with hyperinsulinemia are recognized risk 
factors in diabetic cardiomyopathy. They are also associated with thrombotic 
risk factors like factor VII, factor XII⁶³, elevated plasminogen activator 
inhibitor- 1⁶⁴ and fibrinogen. 
It has a close relationship with C Reactive protein and hypertension 
and studies have revealed worse LV performance in the presence of raised 
CRP levels⁶⁵. 
The link between insulin resistance and obesity has been in studied for 
many decades. Obesity is simply defined by excess if fat in the body and is 
quantified using BMI or body mass index. BMI is given by the formula: 
 	ℎ  	
	ℎ    
 
In South Asian Indians, the BMI is interpreted as normal: 
VALUE INTERPRETATION 
<23 NORMAL 
23 – 25 OVERWEIGHT 
>25 OBESE 
 
33 
 
Insulin resistance is also associated strongly with glucose intolerance. 
It is present in a majority of individuals with type 2 DM, their first degree 
relatives, and also in individuals with impaired glucose tolerance. Therefore , 
the effects of insulin on the diabetic myocardium are closely related to 
systemic  abnormalities and the direct consequences of insulin on the 
vascular system.  
Chief ingredient linked to the development of insulin resistance is TNF 
α⁶⁶. – a cytokine also implicated in inflammation. This insulin resistance is 
linked to various other disorders other than diabetes mellitus like systemic 
hypertension and coronary artery disease. 
It has also been linked to early diastolic abnormalities of left ventricle 
in diabetes as well as systemic hypertension as it has been postulated to be 
associated with left ventricular hypertrophy ⁶⁷  or increased LV mass ⁶⁸. 
Thus, it is evident that various mechanisms act concurrently to cause 
diabetic cardiomyopathy. Since there is no specific therapy for diabetic 
cardiomyopathy it is necessary to know these pathogenic mechanisms well as 
they can act as targets for therapy. 
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INSULIN RESISTANCE SYNDROMES AND ITS COMPONENTS: 
 Central obesity, 
 Increased liver fat, 
 Increased muscle fat, 
 Glucose intolerance and type 2 diabetes mellitus, 
 Alteration in lipids, 
 High triglyceride concentrations, 
 Low HDL cholesterol concentration, 
 Increased coagulation, 
 Increased fibrinogen, 
 Microalbuminuria, 
 Endothelial dysfunction, 
 Hypertension, 
 Increased inflammation. 
Diabetes and heart failure: 
To add a note on diabetes and heart failure, it is a well established fact 
that diabetes mellitus in itself is a recognized and independent risk factor for 
heart failure. In fact, a landmark study called UKPDS showed that the 
incidence of heart failure in patients with diabetes correlated well with 
HbA1c levels⁶⁹. There is increased risk of death also in patients with diabetes 
and heart failure. The aims of treatment include risk reduction and providing 
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medical therapy in the form of ACE inhibitors, β blockers, AR blockers and 
aldosterone antagonists. In particular the use of ACE inhibitors should be 
considered in patients with diabetes and heart failure irrespective of symptom 
severity and in the absence of significant contraindications. This is 
substantiated by various trials using ACE inhibitors like – CONSENSUS, 
SAVE, SOLVD and TRACE. The use of diuretics is beneficial in the setting 
of pulmonary edema and fluid overload. 
Non pharmacologic measures include considering cardiac 
resynchronization therapy, myocardial revascularization and ultimately 
cardiac transplantation⁷⁰.  
Even though diabetes mellitus was a relative contraindication for 
cardiac transplantation studies have reported that well selected patients can 
benefit from transplantation. 
To summarize, 
1. Diabetes mellitus and heart failure frequently exist together and are 
inter related through various pathophysiological mechanisms which are 
complex. 
2. To stratify risk and mange early play a pivotal role to prolong survival 
of the patient. 
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3. Even though there is no clear guidance on the  treatment of heart 
failure and diabetes, it is reasonable and rational to say aggressive 
medical  therapy remains mainstay. 
4. Further randomized trials are necessary to conclusively lay down the 
guidelines for patients with diabetes and heart failure 
Evaluation of diastolic dysfunction and grades of diastolic dysfunction: 
Cardiac cycle has two phases called systole where there is contraction 
either of the atria or ventricles and diastole where there is relaxation  of either 
atria or ventricles. Diastole is usually referred to the period in which the 
myocardial muscle cell generates energy, while in mechanical (as reflected 
by isovolumic deceleration and relaxation phase) and in electrophysiological 
inactivity (there is automatic depolarization)⁷¹. In diastolic dysfunction there 
is a delayed and extended diastolic phase. 
Diastolic dysfunction should first be differentiated from systolic 
dysfunction in which the ejection fraction is reduced due to impaired 
myocardial contractility in contrast to diastolic dysfunction which is 
characterized by impaired myocardial relaxation and normal LV systolic 
function or normal ejection fraction. 
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Assessment of diastolic dysfunction in diabetes mellitus can be done 
by using modern non invasive methods without causing much pain such as 
echocardiography.  
Doppler studies showing transmitral flow are done. The studies measure –  
• Mitral inflow velocities 
• Isovolumic relaxation time 
• Deceleration time  
• Assessment of flow pattern 
Other measurements like size of the left atrium, LV mass etc can also 
be derived. 
During echocardiography, assessment of transmitral flow will help us 
ascertain left ventricle filling patterns. 
As described above, all the various pathogenic mechanisms lead to 
worsening of left ventricular function which initially is reflected by reduction 
in height of E wave and prolongation of deceleration time. As the LV 
functions worsens further, there is elevation of LA pressure and then LV 
filling pressure -increasing E wave and shortening deceleration time. This is 
referred to as pseudonormal and restrictive pattern. 
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Explanation: 
Mitral inflow Doppler – this is used to assess the flow from left atrium 
and left ventricle across the mitral valve during early and also late phases of 
diastole. Transmitral flow velocity is a reflection of the pressure gradient 
between LA and LV. 
Two waves are described. The E wave occurs and is captured during 
the early part of diastole when there is passive filling of the left ventricle. On 
the other hand, velocity of flow of blood during late phase of diastole when 
atrial contraction occurs plays a crucial role in LV filling is represented by A 
wave. 
Traditionally, diastolic dysfunction is classically divided into different 
grades based on the height of E and A waves. 
The velocity of E wave depends largely on the pressure gradient across 
the bicuspid mitral valve and therefore is directly related to pressure in the 
left atrium and inversely related to ventricular compliance. The height of A 
wave in addition depends on pressure in left atrium. 
In general, in individuals aged less than 65 years, it is noted that the 
height of the E wave reflecting passive LV filling is greater than the height of 
A wave and the ratio between the two waves that is E/A ratio typically lies 
between 1.2 and 1.5. 
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As patients age, left ventricular compliance reduces which is 
compounded by the presence of co morbid illnesses like hypertension and 
diabetes mellitus, the height of E wave gradually declines. Initially, the left 
atrial contraction increases to compensate  resulting in increased left atrial 
pressure at which time the height of E wave again rises accompanied by 
decline in the height of A wave resulting in pseudonormal pattern. The reason 
for terming it pseudonormal is that the E/A ratio may come back to normal 
because of the above reasons but in the presence of significant cardiac 
dysfunction. In late stages, worsening of diastolic function of the 
myocardium may result in restrictive pattern. In this the descending slope of 
the E wave becomes increasingly steep as a consequence of abrupt cessation 
of blood flow across the bicuspid mitral valve. Also, the deceleration time of 
the E wave becomes very rapid⁷². 
Therefore, diastolic dysfunction can be divided into four grades using 
Doppler studies as follows: 
Grade 1 LVDD -  characterized by the reversal of  E/A ratio on mitral 
inflow studies. The patients are usually asymptomatic at this stage and this 
stage is considered to be the mildest form of diastolic heart failure and is 
aptly referred by the term -  abnormal relaxation pattern. 
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Grade 2 LVDD – this phase is characterized by increasing filling 
pressure in the LA. The LA may also be increased in size due to increased 
pressure in LA. This phase is considered to be moderate stage disease. The 
pattern is referred to pseudonormal pattern as the E/A ratio may come back to 
normal. 
Grade 3 LVDD -  In this phase, there is restricted filling of the left 
ventricle; both LA and LV pressures are high. The patients are usually 
symptomatic requiring therapy. The pattern is referred to as reversible 
restrictive diastolic dysfunction  as the diastolic abnormalities noted seem to 
reverse with Valsalva manoeuvre performed during echocardiography. 
Grade 4 LVDD – In this phase also, there is restricted filling of the 
left ventricle but the changes are usually not reversible – hence referred to as 
- fixed restrictive diastolic dysfunction. Patients are usually symptomatic to a 
severe degree, require hospitalization and in hospital management. 
There are other methods to assess diastolic dysfunction such as using 
pulmonary venous Doppler flow patterns. 
Normally, the flow in pulmonary vein can be divided into 3 components –  
• S wave – characterized by forward flow from pulmonary veins into left 
atrium during the period of ventricular systole. 
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• D wave – characterized by passive diastolic flow during the period of 
ventricular diastole. 
• AR wave -  characterized  by reversal of flow into pulmonary veins 
during contraction of atrium. 
In the presence of impairment of LV relaxation there is ‘blunting’ of S 
wave which is lower than D wave. The reduced compliance of left ventricle 
may also lead to greater flow into pulmonary veins during atrial contraction⁷³. 
Tissue Doppler imaging: 
This method uses Doppler imaging principles to assess myocardial 
contraction and relaxation. The technique uses filters that optimize the 
assessment of low velocity, high amplitude signals that arise as a 
consequence of myocardial motion. However, important limitations do exist 
like angle dependence. Tissue Doppler imaging is used to assess the diastolic 
phase because of its very high temporal resolution also because of its ability 
to adequately quantify myocardial wall motion velocity accurately – this 
being dependent on the rates of myocardial relaxation and contraction. The 
assessment of the above parameter is usually done by sampling the mitral 
annular motion. 
The mitral annulus is noticed to move longitudinally towards the apex 
of the heart which usually remains fixed, in systole and stays away from apex 
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during the phase of diastole. Both medial and lateral annulus velocities can be 
sampled using Doppler imaging  and the parameters which can be inferred 
include – systolic contraction ( S'), early diatolic relaxation velocity (E') and 
also late diastolic relaxation velocities (A'). 
In this regard, E' relates to rate of relaxation of myocardium during 
early diastolic phase and inversely related to tau – which is the time constant 
of relaxation of ventricle. The E' velocity is variable according to different 
age groups. 
The parameter E/E', where E indicates the standard mitral E wave 
velocity gives us a measure that has been found to clearly correlate well with 
filling pressure. Dividing E/E' gives a measure that reflects pressure in the 
left atrium and it is found that this itself depends on left ventricular end 
diastolic pressure. 
One of the other methods used for assessing diastolic dysfunction 
using echocardiography includes measurement of isovolumic relaxation time 
or simply IVRT. This reflects the time interval between aortic valve closure 
and beginning of ventricular filling. Abnormal relaxation og left ventricle 
correlates with prolongation of isovolumic relaxation time; although a 
decrease in IVRT can occur in patients with a restrictive pattern of left 
ventricular filling. 
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Cardiac catheterization can be done for evaluating LV isovolumic 
relaxation rhythm and also LV isovolumic contraction time for more accurate 
measurement of diastolic myocardial function. 
Mitral or E wave, deceleration time indicates the time taken from peak 
mitral inflow of blood to cessation of flow across mitral valve. There is, 
however, a drawback. In the early phase of diastolic dysfunction the 
decleration time can increase making the interpretation all the more difficult. 
Pitfalls in the assessment of diastolic dysfunction using 
echocardiography: 
• Grades of diastolic dysfunction does not usually correlate very well 
with clinical outcomes. 
• Diastolic dysfunction is extremely common in patients with systemic 
hypertension and also elderly individuals making interpretation 
difficult. 
• Diastolic abnormalities are not necessarily associated with clinical 
symptoms or overt heart failure. 
On occasions it may be difficult to assess subtle diastolic abnormalities 
and in order to unmask abnormalities in diastolic function – diastolic function 
during exercise is done. This is otherwise called as “diastolic stress test.” 
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Other uses of echocardiography in addition to assessing diastolic dysfunction 
include: 
• Assessment of  LV Volume 
• Assessment of LV systolic function 
• Assessment of LA size 
LV structure - size and mass: 
Based on the assumption that the left ventricle approximates a prolate 
ellipsoid, the LV volume can be estimate using either linear or two 
dimensional measurements. 
The Simpson method of discs (single plane or bi plane) does not rely 
on rigid geometric assumption and therefore has been demonstrated to be 
more superior and accurate in measuring left ventricular volume. This is 
important because the left ventricular geometry may change to a significant 
extent in conditions such as after myocardial infarction. 
The above said method requires accurate identification of endocardial 
border in apical four and two chamber views with the assistance of computer 
to measure the diameter of equally distributed slices along the left ventricle. 
The ideal method would however be to use three dimensional 
echocardiography as it has potential to decrease some of the many limitations 
of two dimensional echocardiography. 
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LV mass can be calculated  using various formulae which take into 
account parameters such as chamber size and wall thickness. LV mass index 
however involves the use of height and weight in addition to those 
parameters used for LV mass determination. 
A major pitfall is that accuracy of LV mass measurement is greatly 
reduced in the setting of altered ventricular geometry such as after 
myocardial infarction.LV hypertrophy is defined by a wall thickness of 12 
mm or more. 
LV systolic function: 
LV systolic function can be assessed by various methods using 
echocardiography. The left ventricular ejection fraction or simply LVEF 
reflects left ventricular systolic function. It is given by the formula: 
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×  100 
and this is reported as a percentage. Generally, LV function is 
estimated visually although it requires assessment from calculation using 
ventricular volumes. Even in such a situation the accuracy of measurement is 
affected by various factors like – definition of endocardial border, quality of 
image, geometry of ventricle etc. 
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Several other methods are available for assessment of systolic function.  
The Tei index, also known as myocardial performance index is aptly 
defined as the sum of  isovolumic contraction time and isovolumic relaxation 
time divide by the ejection time. This takes into account both  -  diastolic and 
systolic performance. The lower the index, better the performance. 
ADVANTAGES OF TEI INDEX: 
1. It is an excellent marker for myocardial performance. It is not 
influenced by high left atrial loading pressure which is usually present 
in the later stages of diastolic heart failure. Hence, it may become an 
important tool for early diagnosis of upcoming ischemia of 
myocardium. 
2. In elderly, it serves as a significant prognostic marker of cardiovascular 
mortality and morbidity. 
3. Increased TEI index is associated with increased incidence of 
ventricular arrythmogenecity. 
DISADVANTAGES OF TEI INDEX: 
It does not allow evaluation of pathological substrate of myocardial 
dysfunction – because it does not evaluate myocardial pressure levels during 
ventricular filling levels in diastole. 
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It is therefore important to assess systolic function because it can aid in 
diagnosis, monitor therapy and risk sratification of various cardiovascular 
diseases.  
Assessment of LA size: 
Several methods can be used to quantify the size of left atrium 
accurately. One can obtain a linear measurement of left atrium in the 
parasternal long axis view. LA area can be accurately assessed from apical 
view. The volume of left atrium can be calculated using Simpson’s biplane 
methods to the apical four chamber and two chamber view. The volumes 
obtained however, should be adjusted to body size. The function of left 
atrium with regard to the cardiac cycle can also be calculated. There are three 
important phases of left atrial function: 
PHASES DESCRIPTION 
Reservoir phase 
Atrium fills up rapidly due to inflow from 
pulmonary veins during early LV systole 
Conduit phase 
Emptying of left atrial blood into left ventricle 
passively due to early LV systole 
Contractile phase 
Augmentation of left ventricular filling by atrial 
contraction in late diastolic phase 
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Thus, both -  active and passive emptying volumes of left atrium can 
be assessed. 
LA passive emptying – given by maximal volume of LA – LA volume 
during atrial contraction. 
LA active emptying – LA volume before atrial contraction  -  minimal 
LA volume. 
LA enlargement has been linked to various adverse cardiovascular 
outcomes. There are numerous causes of LA enlargement including those due 
to LV diastolic and systolic dysfunction and atrial fibrillation. LA size 
reflects LV filling pressure and hence can reflect diastolic abnormalities⁷⁴. 
INTERACTION WITH HYPERTENSION: 
The morphological and clinical features of heart disease in diabetics 
with concurrent hypertension are more severe than those with diabetes or 
those with hypertension alone. Experimental studies have revealed that the 
interstitial connective tissue deposition is greater when the two diseases are 
present simultaneously. Besides it was also evident that the myocardium was 
susceptible to myocyte necrosis when the two were present together.  
Hypertension can also be secondary to diabetes  because sustained 
hyperglycemia has been shown to increase the blood pressure in animal 
models and this has been linked to angiotensin II. Also, it is found that there 
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is premature appearance of heart failure in such patients, and even when it 
occurs the progression is very rapid and the prognosis is very poor. 
Association between hypertension and diabetes: 
• Hypertension associated with type 2 diabetes mellitus (insulin 
resistance, syndrome X, metabolic syndrome) 
• Hypertension associated with nephropathy in type 1 DM. 
• Coincidental hypertension in patients with diabetes: 
 Essential hypertension 
 Isolated systolic hypertension 
 Renal scarring (from recurrent pyelonephritis) 
• Diabetogenic antihypertensive drugs – these include 
 Potassium losing diuretics (chlorthalidone, high dose thiazide 
diuretics. 
 Β blockers (high dose) 
 Combined diuretics and β blockers 
• Drugs implicated in causing obesity, hypertension and glucose 
intolerance: 
 Glucocorticoids 
 Combined oral contraceptive pills 
 Antipsychotics 
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• Endocrine disorders causing hypertension and glucose intolerance: 
 Acromegaly 
 Cushing’s syndrome 
 Conn’s syndrome  
 Pheochromocytoma⁷⁵ 
Thus the above causes should be kept in mind while evaluating cardiac 
function in patients with diabetes and hypertension. 
Investigation in patients with diabetes and hypertension: 
Initial investigations in type 2 DM with hypertension aims to initially 
rule out the rare causes of secondary hypertension; to assess the degree of 
tissue damage caused by both disorders and to identify other risk factors for 
the presence of vascular disease. 
In obtaining medical history the following questions should be 
compulsorily addressed: 
• Presence of cardiovascular symptoms 
• Presence of previous urinary disease 
• Smoking and alcohol abuse 
• Previous  or current medication history 
• Family history of hypertension and cardiovascular disease 
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On examination of the patient, the following factors should be observed 
very carefully: 
• Careful examination of blood pressure both -erect and supine and 
documentation 
• Any evidence of left ventricular hypertrophy 
• Any evidence of heart failure 
• All peripheral pulses including a search for bruit 
• Ankle -  brachial index 
• Fundus examination to check for changes of both diabetes and 
hypertension. 
Patient should be investigated and the following aspects need special 
mention: 
Electrocardiographic evidence of alteration in rate or rhythm, ischemic 
changes and evidence of left ventricular hypertrophy. 
Chest X Ray evidence of cardiac enlargement and features of acute 
pulmonary edema. 
Echocardiographic evidence of systolic function, ischemic changes 
suggested by regional wall motion abnormalities, dimensions such as LV 
mass and LA size, grading of diastolic dysfunction, assessment of ejection 
fraction etc. 
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Other routine blood investigations like renal function tests indicating 
renal dysfunction, if present and urine examination to detect 
microalbuminuria⁷⁶ should be done. 
Treatment of hypertension in diabetes: 
It is absolutely necessary to treat hypertension in diabetes to delay 
progression to various complications. Various trials conducted such as the 
HOPE trial ( hypertensive optimal treatment and control ), ABCD trial ( 
appropriate blood pressure control in diabetes) and FACET trial ( Fosinopril 
versus amlodipine  cardiovascular events randomized trial showed that 
optimal control of blood pressure in diabetes reduced the risk of 
cardiovascular events⁷⁷. 
The recent JNC 8 guidelines also recommend that a target level of 
systolic blood pressure of  ≤ 140 mmHg and a diastolic blood pressure of ≤ 
90 mmHg  is optimal to prevent adverse cardiovascular outcomes. 
The following measures can be adopted to retard the progression of 
cardiovascular outcome in patients with diabetes and hypertension:- 
• Non pharmacologic measures: this includes 
 Weight reduction by exercise -  30 minutes of brisk walking per day 
for at least 5 days in a week. 
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 Salt restricted diet and avoiding foodstuffs with high salt content 
 Diet modification -  adoption of a diet rich in vegetables and fruits, 
and reduced consumption of  foods rich in saturated fat. 
 Smoking cessation. 
 Alcohol restriction -  not more than 2 – 3 units per day in men and 2 
units per day in women. 
When followed correctly the systolic and diastolic blood pressure can 
be reduced as much as 11 mmHg and 8mmHg respectively equivalent to 
many antihypertensive drugs. Thus, it is evident that lifestyle modifications 
indeed make a lot of difference in not only preventing the development of 
disease but also delays the development of complications once it has already 
developed. 
• Pharmacological measures: 
There are various classes of antihypertensive drugs  available in the 
market for the treatment of systemic hypertension. Current guidelines 
recommend the use of four classes of drugs for control of blood pressure. 
These include ACE inhibitors like captopril, enalapril etc., Angiotensin 
receptor blockers like losartan, valsartan etc., Thiazide diuretics like 
chlorthalidone, hydrochlorothiazide etc. and Calcium channel blockers like 
amlodipine etc. 
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The other classes of antihypertensives are used in special situations. 
The choice of antihypertensives depends on a variety of factors like 
age of the patient, volume status of the patient, presence of diabetes and 
hypertension, presence of complications like renal failure and hence the use 
of antihypertensives should be individualized. By and large, thiazide diuretics 
are found to be very effective in the management of patients with systemic 
hypertension. But, ACE inhibitors or AR blockers are preferred in patients 
with both diabetes and hypertension as they are found to retard the 
progression of microalbuminuria. 
DYSLIPIDEMIA IN DIABETES: 
On a comparative standpoint, targeting or treating patients with 
dyslipidemia effectively in diabetes has shown to be more effective in 
preventing macrovascular complications. The increased glycation of 
lipoproteins deserve special mention as it has direct effects on the metabolism 
of lipoproteins. These glycated lipoproteins are handled ina different way by 
lipoprotein receptors , particularly of the scavenger group, hence promoting 
atherogenesis. 
Increased glycation also enhances the effects of oxidative stress on 
lipoproteins and hence affects both type 1 and type 2 diabetics. 
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The term used to describe such a situation is diabetic dyslipidemia which is 
characterized by elevated triglycerides, small dense low density lipoproteins 
and low high density lipoprotein concentration. 
Some of the features implicated in the development of diabetic 
dyslipidemia includes: 
• Influence of insulin on liver apolipoprotein production 
• Down regulation of lipoprotein lipase in contrast to hepatic lipase 
• Enhanced cholesteryl ester transfer activity protein 
• Peripheral actions of insulin on adipose tissue and muscle 
It is therefore necessary to control dyslipidemia in diabetics⁷⁸. 
Various trials such as the 4S trial( Scandinavian Simvastatin Survival 
Study) and CARE trial (Cholesterol and Recurrent Events) established the 
fact that a decrease in blood lipid concentration reduced cardiovascular 
mortality. Another trial called the MRFIT ( Multiple Risk Factor Intervention 
Trial) showed a curvilinear relationship between coronary heart disease 
mortality and total cholesterol levels in diabetic men with a four fold 
increased risk in diabetic men. 
Based on these findings, it is prudent to maintain a LDL level of ≤ 100 
mg/dl with the use of statins, and fibrates are added if the triglyceride levels 
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are ≥ 200 mg/dl. Rhabdomyolysis is a major concern when the two drugs are 
used together. 
The American Diabetes association recommends that lipid profile 
consisting of LDL, HDL , total cholesterol and triglyceride levels be checked 
on an annual basis⁷⁹. 
The treatment of dyslipidemia can be divided into non pharmacological 
and pharmacological measures: 
• Non pharmacological measures: 
These include measures such as life style modification including 
smoking cessation, restricted alcohol consumption, increased physical 
activity and dietary modifications. 
• Pharmacological measures: 
Use of statins -  Statins have pleiotropic effects. They act by inhibiting 
the enzyme HMG Co A reductase , a key enzyme involved in cholesterol 
synthesis. As a result there is increased clearance of LDL cholesterol from 
blood and also decreased hepatic production of VLDL and LDL. 
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Other pleiotropic effects include: 
• Decrease in the level of CRP or C Reactive Protein 
• Increase in the collagen content of atherosclerotic plaque 
• Alteration in the function of endothelium 
• Decrease in the inflammatory component of plaque 
The statins currently in use are atorvastatin, fluvastatin, simvastatin, 
pravastatin etc. There are many drugs which can affect the metabolism of 
statins. 
The major side effects of statins are chiefly related to muscle 
symptoms which range from diffuse myalgias to myositis, defined by the 
presence of diffuse muscle pain with obvious evidence of muscle 
inflammation in the form of raised CK levels. They also cause reversible 
elevation of transaminases. They are however well tolerated by the patients 
only rarely requiring drug discontinuation⁸⁰. 
Diabetes and metabolic syndrome: 
Most patients with diabetes mellitus also have metabolic syndrome or 
syndrome X characterized by the following features: 
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CRITERIA DESCTRIPTION 
Obesity 
Waist circumference 
> 40 cm in males 
> 35 cm in females 
Hyperglycemia 
Fasting plasma glucose ≥ 100 mg/dl 
or is on treatment for the same 
Dyslipidemia 
Triglyceride level ≥ 150 mg/dl or on 
treatment for the same 
Dyslipidemia 
HDL level 
<40 mg/dl in malea 
< 50 mg/dl in females 
Hypertension 
>135 mmHg systolic and 
>85 mmHg diastolic 
 
Any 3 of the above criteria are sufficient to make a diagnosis of 
metabolic syndrome.  
Various other organizations have mentioned different criteria for the 
diagnosis of metabolic syndrome. 
The presence of metabolic syndrome in a patient with diabetes mellitus 
should prompt intensive therapy, else cardiovascular outcomes occurs at a 
much faster and earlier rate and mortality is very high. 
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INTERACTION WITH ISCHEMIC HEART DISEASE: 
There is accelerated atherosclerosis in patients with diabetes mellitus 
which makes them prone to ischemic heart disease. The atheromatous lesions 
occur much earlier, very rapidly and are present in greater density in patients 
with diabetes mellitus. The atheromata are extensive, diffuse and involves the 
distal vessels in both peripheral and coronal circulation⁸¹. There are various 
reasons for the accelerated atherogenesis some of which are: 
• Abnormalities in lipid metabolism such as high levels of lipoprotein (a) 
• Increased Angiotensin II 
• Endothelial dysfunction 
The above factors together with many more result in accelerated 
atherogenesis which is influenced both by duration of diabetes and diabetes 
control. 
STAGES OF DIABETIC CARDIOMYOPATHY⁸²: 
A classification system has been proposed by Maisth et al for diabetic 
cardiomyopathy. This includes: 
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(A) Stage 1 diabetic cardiomyopathy: 
Heart failure with preserved ejection fraction or simply HFPEF – this 
is the earliest form of diabetic cardiomyopathy and is detected in 
approximately 75% of asymptomatic diabetic patients. 
Relevant CAD, valvular disease and uncontrolled hypertension are 
usually not present. 
(B) Stage 2 diabetic cardiomyopathy 
Systolic and diastolic heart failure with dilatation and reduced ejection 
fraction. CAD, uncontrolled hypertension and valvular heart disease are 
usually not present. 
(C) Stage  3 diabetic cardiomyopathy 
Systolic and/or diastolic heart failure in diabetes with small vessel 
disease. There is presence of microbial infection and/ or inflammation and/or 
hypertension without CAD. 
Hypertension, microangioapathy and myocarditis can be contributory. 
(D) Stage 4 diabetic cardiomyopathy 
Heart failure attributed to infarction or ischemia and also there is 
significant remodelling in addition to stage 3. In this stage the term usually 
used is heart failure in diabetes or stage 4 diabetic cardiomyopathy. 
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THERAPEUTIC INTERVENTIONS FOR DIABETIC 
CARDIOMYOPATHY: 
(A) Diabetes control:  
Prompt, early and appropriate therapy of diabetes is important as it 
improves myocardial function. The UKPDS study( United Kingdom 
Prospective Diabetes Study) did not actually reveal a significant benefit of 
intensive control of blood glucose o  the risk of developing microvascular 
disease. However, the trial had some pitfalls which include: 
(a)methodological pitfalls in that the study was not blinded and 
(b) the study  continued when no difference was observed at the initial 
agreed time point for analysis.  
In contrast, the other studies have consistently revealed that early and 
intensive blood glucose control resulted in delayed development of 
cardiovascular outcomes and also microvascular complications. The control 
of glucose can be done with the help of various non pharmacologic and 
pharmacologic measures. 
a. Non pharmacologic measures: 
This chiefly includes lifestyle modification like increasing physical 
activity, diet modification- decreased consumption of foodstuffs with high 
glycemic index and avoidance of sweets, increased consumption of diet rich 
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in fibre content which not only helps in causing satiety but also helps in 
reducing weight. Other measures include as those described in the treatment 
of hypertension and dyslipidemia. 
Patients should be educated regarding self monitoring of blood glucose which 
can help them make alterations in treatment. 
b. Pharmacological measures 
Various classes of oral antidiabetic agents are used nowadays. The 
most commonly prescribed initial drugs are biguanides like metformin and 
second generation sulfonylureas like glipizide, glibenclamide and 
glimiperide. Metformin is an insulin sensitizer and reduces blood glucose 
levels chiefly by decreasing hepatic glucose output – “plug’s the leaky liver” 
and also gluconeogenesis it also improves peripheral glucose uptake. The 
drug is excreted by the kidney and hence cannot be administered if CRCl < 
30 ml/min. 
In addition, there are other classes of oral drugs like thiazolidinediones, 
alpha glucosidase inhibitors and the newer ones like GLP 1 analogues, DPP 4 
inhibitors. The most recent is SGLT 2 inhibitors like canagliflozin. 
Insulin therapy must be initiated early in patients with type 2 diabetics 
because it lowers the HbA1c values more efficiently. Therapy with oral drugs 
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or insulin is shown to decrease the structural and functional changes in the 
diabetic myocardium to some extent. 
The choice of drugs used depends on various factors like the type of 
diabetes, the age of the patient, volume status of the patient, pharmacokinetic  
properties, side effect profile, the presence or absence of real dysfunction, the 
risk of hypoglcemia and presence of co morbid illnesses. 
In developing countries another chief determinant is the cost of the 
drug. GLP 1 analogues deserve special mention. They have an impact on 
glucose metabolism and therefore on diabetes. The first drug to be marketed 
was exenatide and data revealed a significant reduction in HbA1c levels. 
They have been associated with improvement in various hemodynamic 
variables in patients with diabetes mellitus but without symptoms of overt 
heart failure. It was also noted there was significant improvement in cardiac 
parameters post infarction and in advanced heart failure⁸³. Thiazolidinediones 
are generally not preferred due to their influence on cardiovascular morbidity 
and mortality. The other classes of drugs are being tested for their accuracy. 
(B) Treatment of fibrosis: 
It is now well established that renin- angiotensin –aldosterone system 
or simply RAA system plays an important role in the pathogenesis of diabetic 
cardiomyopathy. The ACE inhibitors like ramipril, enalapril, etc. can prevent 
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myocardial fibrosis, cardiac hypertrophy and myocardial mechanical 
dysfunction. They have also shown to prevent another important feature – 
coronary artery perivascular fibrosis and interstitial collagen deposition⁸⁴.  
(C) Other novel therapies targeting diabetic cardiomyopathy -these 
include: 
(A) AGE INHIBITORS  -aminoguanidine, alanine aminotranferase946  
and pyridoxamine. 
(B) Copper chelating agents like trientene 
(C) Modulators  of free fatty acid metabolism – Trimetazidine. 
Other aspects in the management of diabetes mellitus: 
Keeping in the mind the complex interplay of various metabolic 
pathways and organ systems in diabetes mellitus – it is necessary to screen 
patients with diabetes for complications and treat them accordingly. 
 Patients should be advised not to skip meals and avoid heavy meals 
and adhere to medications strictly. 
 Patients should be taught to identify symptoms such as 
breathlessness, fatigue, abdominal pain, vomiting suggestive of 
acute complications like diabetic ketoacidosis. 
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 Patients should be screened for macrovascular complications like 
coronary heart disease and peripheral vascular disease. 
 Patients should be screened for microvascular complications like 
diabetic retinopathy, neuropathy and in particularly nephropathy. 
The development of nephropathy in patients with diabetes mellitus 
indicates advanced disease and the condition has to be aggressively 
treated. The treatment has two important advantages. The 
progression to end stage renal disease can be delayed and also 
cardiovascular morbidity and mortality can prevented. 
 Patients should be advised on maintainence of proper oral hygiene. 
 Patients should be instructed on care of the feet – they should be 
advised to examine the foot daily for any wounds which are not 
healing, sensations, toes and toe clefts etc. They should be 
instructed to meet the physician every 3 months for examination of 
sensation and vibration in the feet. 
 Diabetics are also prone for infections. They should be educated to 
identify the symptoms, seek medical attention for treatment. In 
particular, they are prone for skin and subcutaneous infections, 
urinary tract infections etc. 
 Patients with diabetes can also have sexual dysfunction and they 
should be instructed to seek medical help. 
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 Depression among diabetic individuals is high. They should be 
identified and treated accordingly. 
Therefore, treatment of diabetes does not stop with control of blood 
sugar levels alone; it also involves identification, monitoring and treating the 
complications in addition to emphasizing on self management. 
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MATERIALS AND METHODS: 
The study was conducted at the Institute Of Internal Medicine, Rajiv 
Gandhi Goverment General Hospital, and Madras Medical College, Chennai. 
ETHICAL COMMITTEE APPROVAL: 
Obtained. 
CONSENT: 
Written informed consent obtained. 
STUDY DURATION: 
April 2015 to September 2015. 
STUDY POPULATION: 
Patients attending the outpatient department of Institute of Internal 
Medicine and also patients admitted under Institute of Internal Medicine who 
satisfy inclusion and exclusion criteria. 
SAMPLE SIZE: 
One hundred individuals. 
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TYPE OF STUDY: 
Observational study. 
INCLUSION CRITERIA: 
• Type 2 diabetics – newly detected and of any duration with or without 
treatment who are less than 60 years of age. 
EXCLUSION CRITERIA: 
Patients with - 
• Hypertension,  
• Coronary artery disease, 
• Pregnant women,  
• Pre existing heart disease, 
• Clinical evidence of macrovascular disease like stroke, MI, peripheral 
vascular disease, 
• Clinical evidence of microvascular disease. 
DATA COLLECTION AND METHODS: 
Relevant history was obtained from the subjects as per the 
questionnaire and the patient is also subjected to detailed physical 
examination. Informed as well as written consent was obtained from either 
the patients themselves or their legal representatives. Cases were screened 
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according to inclusion and exclusion criteria. Blood investigations were 
collected from the patients. Age, duration of diabetes, medication status, past 
history of coronary artery disease, peripheral vascular disease or stroke were 
obtained from self report. Patients were also screened for microvascular 
complications like retinopathy, nephropathy and neuropathy. Blood pressure 
was recorded using standardized sphygmomanometer. Investigations 
collected included renal function tests include electrolyte panel, liver function 
tests, complete hemogram, lipid profile and urine routine. Electrocardiograph 
and echocardiograph were performed. HbA1c levels were also obtained. The 
data collected were entered into the proforma and subjected to statistical 
analysis. 
STATISTICAL ANALYSIS: 
Analysis was done using SPSS Version 20. Significance was assumed 
with a p value of 0.05. Association between two categorical variables was 
done using chi square test. All p values were two tailed and significant when 
values were less than 0.05. 
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OBSERVATION AND RESULTS 
 
DATA OBTAINED FROM THE STUDY: 
CHART 1 : MEAN HbA1C AND GRADES OF  
DIASTOLIC DYSFUNCTION 
 
GRADES OF 
DIASTOLIC 
DYSFUNCTION 
N 
(SAMPLE) 
MEAN 
HbA1C 
STANDARD 
DEVIATION 
 
NO GRADE 15 7.450 0.5574 
F VALUE – 
102.036 
P VALUE - 
<0.001 
GRADE 1 48 8.946 0.8932 
GRADE 2 27 10.341 0.9271 
GRADE 3 10 13.360 1.2791 
TOTAL 100 9.519 1.8145 
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CHART 2: MEAN DURATION OF DIABETES IN  
MONTHS AND GRADES OF DIASTOLIC DYSFUNCTION  
 
GRADES OF 
DIASTOLIC 
DYSFUNCTION 
N 
(SAMPLE) 
MEAN 
DURATION 
IN 
MONTHS 
STANDARD 
DEVIATION 
 
NO GRADE 15 11.250 12.1463 F VALUE 
– 209.379 
P VALUE 
- <0.001 
GRADE 1 48 60.250 15.9447 
GRADE 2 27 119.556 24.1109 
GRADE 3 10 182.400 29.8262 
TOTAL 100 80.436 52.7934 
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CHART 3: MEAN AGE IN YEARS AND GRADES OF  
DIASTOLIC DYSFUNCTION 
 
GRADES OF 
DIASTOLIC 
DYSFUNCTION 
N 
(SAMPLE) 
MEAN 
AGE IN 
YEARS 
STANDARD 
DEVIATION 
 
NO GRADE 15 48.875 3.9306  
F VALUE – 
23.273 
P VALUE - 
<0.001 
GRADE 1 48 50.521 4.4050 
GRADE 2 27 56.481 3.1910 
GRADE 3 10 57.600 3.3400 
TOTAL 100 52.554 5.0941 
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CHART 4:  LV MASS AND GRADES OF DIASTOLIC 
DYSFUNCTION 
GRADES OF 
DIASTOLIC 
DYSFUNCTION 
N 
(SAMPLE) 
MEAN LV 
MASS IN 
GRAMS 
STANDARD 
DEVIATION 
 
NO GRADE 15 93.500 14.8369 
F VALUE – 
73.276 
P VALUE - 
<0.001 
GRADE 1 48 201.917 32.2720 
GRADE 2 27 226.889 36.5412 
GRADE 3 10 249.300 36.2861 
TOTAL 100 196.109 56.8127 
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CHART 5:  LA SIZE AND GRADES OF DIASTOLIC DYSFUNCTION 
 
GRADES OF 
DIASTOLIC 
DYSFUNCTION 
N 
(SAMPLE) 
MEAN 
LA SIZE 
IN MM 
STANDARD 
DEVIATION 
 
NO GRADE 15 25.419 0.6635  
F VALUE 
– 34.966 
P VALUE 
- <0.001 
GRADE 1 48 26.715 4.1241 
GRADE 2 27 31.059 1.8923 
GRADE 3 10 35.670 1.5449 
TOTAL 100 28.557 4.3773 
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CHART 6: OHA AND INSULIN CROSS TABULATION 
 
GRADES OD DIASTOLIC 
DYSFUNCTION TOTAL 
NO 1 2 3 
 
I 
COUN T 0 26 17 0 43 
% WITH INSULIN 0 60.5 39.5 0 100 
% WITH DIASTOLIC 
DYSFUNCTION 0 54.2 63 0 42.6 
O+1 
COUN T 0 0 10 10 20 
% WITH INSULIN 0 0 50 50 100 
% WITH DIASTOLIC 
DYSFUNCTION 0 0 37 100 19.8 
0 
COUN T 15 22 0 0 38 
% WITH INSULIN 42.1 57.9 0 0 100 
% WITH DIASTOLIC 
DYSFUNCTION 100 45.8 0 0 37.6 
 
COUN T 15 48 27 10 100 
% WITH INSULIN 15.8 47.5 26.7 9.9 100 
% WITH DIASTOLIC 
DYSFUNCTION 100 100 100 100 100 
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CHART 7: DIASTOLIC DYSFUNCTION AND SEX 
 
 
 
 
 
SEX 
 
 
GRADES OF DIASTOLIC 
DYSFUNCTION TOTAL 
NO 1 2 3 
F 
COUNT 7 26 15 5 53 
% WITH 
DIASTOLIC 
DYSFUNCTION 
43.8 54.2 55.6 60 53.5 
M 
COUNT 9 22 12 4 47 
% WITH 
DIASTOLIC 
DYSFUNCTION 
56.2 45.8 44.4 40 46.5 
 
TOTAL 
COUNT 16 48 27 9 100 
% WITH 
DIASTOLIC 
DYSFUNCTION 
100 100 100 100 100 
 
 
 
 
 
 
 CORRELATION BETWEEN HbA1c LEVELS AND 
GRADES OF DIASTOLIC DYSFUNCTION
 
 
Bar diagram indicating mean HbA1c levels and grades of diastolic 
dysfunction. 
F value – 102.036
P value - < 0.001
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Line diagram indicating correlation between HbA1c levels  
with grades of diastolic dysfunction. 
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 Bar diagram indicating mean duration of type 2 diabetes in 
months and grades of diastolic dysfunction.
F value – 209.379 
p value <0.001 
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Line diagram indicating correlation between mean age of patients  
in years and grades of diastolic dysfunction. 
F value 23. 273  
P value <0.001 
 
 
  
0
10
20
30
40
50
60
GRADE 0 GRADE 1 GRADE 2 GRADE 3
GRADES OF DIASTOLIC DYSFUNCTION
n(Sample)
mean age in years
standard deviation
81 
 
 
LV MASS (LINEAR VIEW) AND DIASTOLIC DYSFUNCTION 
F value -73.276  
p value <0.001 
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LA SIZE AND GRADES OF DIASTOLIC DYSFUNCTION 
 
F value - 34.966  
p value <0.001 
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TOTAL NUMBER OF MALES AND FEMALES IN THE STUDY 
 
 
MALES :  46 
FEMALES :  54 
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MALES AND DIASTOLIC DYSFUNCTION 
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FEMALES AND DIASTOLIC DYSFUNCTION 
 
 
CHI SQUARE TEST -0.836 ,  
df  -3,  
p value -0.841 (not significant) 
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DISCUSSION 
A total of hundred patients were selected for the study which included 
both males and females. The study was conducted in the institute of internal 
medicine, Rajiv Gandhi Government General Hospital. Cases were selected 
from both inpatient and outpatient departments. The male population 
amounted to 46 and female population amounted to about 54. Routine 
investigations were performed. Serum glycated haemoglobin was  determined 
by high performance liquid chromatography. ECG and echocardiography was 
performed for all tghe patients and the results were tabulated. 
The data was documented and subjected for statistical analysis. 
The following parameters or endpoints were focused upon: 
1. To correlate serum HbA1c levels with grades of diastolic dysfunction. 
2. To correlate mean age of the patient with diastolic dysfunction. 
3. To correlate mean duration of type 2 diabetes mellitus and grades of 
diastolic dysfunction. 
4. To correlate LA size and LV mass with grades of diastolic dysfunction. 
5. To observe the number of patients on different therapeutic modalities 
for diabetes mellitus –either oral antidiabetic agents or oral agents plus 
insulin therapy or on insulin therapy alone. 
6. To correlate diastolic dysfunction with sex. 
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Statistical analysis was performed and results were derived to find if 
statistically significant correlation existed or not. 
1. Correlation of serum glycated haemoglobin levels and grades of 
diastolic dysfunction  in asymptomatic type 2 diabetics: 
The tests performed included analysis of variance. It was found that the 
correlation between mean serum glycated haemoglobin levels and grades of 
diastolic dysfunction was statistically significant with a p value of < 0.001. 
It was found that around 48 patients with type 2 DM –both males and 
females included had a mean HbA1c levels of 8.94 and grade 1 LVDD and 
likewise 27 patients had mean HbA1c levels of 10.34 and grade 2 LVDD. 
The 10 patients who had a mean HbA1c level of 13.36 had grade 3 LVDD.15 
patients were found to have no LVDD. The study was similar to other studies 
which demonstrated a direct correlation between HbA1c levels and grades of 
diastolic dysfunction⁸⁵. 
2. Correlation of mean age of patient with grades of diastolic 
dysfunction. 
The tests performed included analysis of variance. It was found that the 
correlation between mean age of patients and grades of diastolic dysfunction 
was statistically significant with a p value of < 0.001. 
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It was found that around 48 patients with type 2 DM –both males and 
females included had a mean age of 50 yrs and grade 1 LVDD, likewise 27 
patients had mean age of 56.48 and grade 2 LVDD. The 10 patients whose 
mean age was 57.6 years had grade 3 LV diastolic dysfunction. 
3. Correlation between mean duration of diabetes in months and grades 
of diastolic dysfunction: 
The tests performed included analysis of variance. It was found that the 
correlation between mean duration of diabetes in months and grades of 
diastolic dysfunction was statistically significant with a p value of < 0.001. 
It was found that around 48 patients with type 2 DM –both males and 
females included had a mean duration of diabetes for 60 months and grade 1 
LVDD, likewise 27 patients had mean duration of diabetes for 119.55 months 
and grade 2 LVDD. 10 patients who had grade 3 LVDD had diabetes for a 
mean duration of 182.4 months. The study results were comparable to other 
studies in which higher grades of diastolic dysfunction correlated with 
increased duration of diabetes mellitus. 
4. Correlate LA size and LV mass with grades of diastolic dysfunction. 
The normal LV mass depends on the age and sex of the patients. 
Usually it is between 67 -162 grams in women and 88 -224 in men. 
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It was however noted that there existed a statistically significant 
correlation between LV mass and grades of diastolic dysfunction. 10 
diabetics with grade 3 LVDD had a mean LV mass of 249 gms. On the other 
hand 27 diabetics with grade 2 LVDD had mean LV mass of 226.8 gms. 
Lastly, 48 diabetics with grade 1 LVDD had mean LV mass of 201.9 gms. 
The results were found to be statistically significant with a p value of 
less than 0.001. A study performed by Voulgeri CH, Tentolouris N, 
Moyassakis I et al revealed similar results⁸⁶. 
The normal LA size also depends on the age and sex of the individual. 
The usual reference range is  27 -33mm in women and 30 -40 in men.In the 
study, it was inferred that there exists a statistically significant relationship 
between LA size and grades of diastolic dysfunction. 
10 diabetics with grade 3 LVDD had a mean LA size of 35.6 mm. On 
the other hand it was noted that 27 patients with grade 2 LVDD had a mean 
LA size of 31.05mm. 48 diabetics with grade 1 LVDD had mean LA size of 
26.71 mm. 
The results were statistically significant with a p value of less than 0.001. 
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5. Correlation  between grades of diastolic dysfunction and sex: 
The study revealed that a statistically insignificant correlation existed 
between grades of diastolic dysfunction and sex of the individual with a p 
value of 0.841. 
Lastly, observations were made regarding the therapeutic modalities in 
type 2 diabetics and it was found that most patients with higher grades of 
diastolic dysfunction required dual therapy including oral antidiabetic agents 
and insulin therapy. 
Thus it was concluded that poorly controlled hyperglycemia had a poor 
outcome with respect to cardiovascular function. 
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CONCLUSIONS 
The study revealed the following conclusions: 
Type 2 diabetics with a poorly controlled blood sugar levels had poor 
cardiovascular function. This is revealed in the form of: 
1. Statistically significant correlation between mean HbA1c levels and 
grades of diastolic dysfunction. 
2. Statistically significant correlation between duration of diabetes and 
grades of diastolic dysfunction. 
3. Statistically significant correlation between age of patients and grades 
of diastolic dysfunction. 
4. Statistically significant correlation between  LV mass and grades of 
diastolic dysfunction. 
5. Statistically significant correlation between LA size and grades of 
diastolic dysfunction. 
6. Statistically insignificant correlation between grades of diastolic 
dysfunction and sex. 
The study in turn highlights the fact that screening of patients with 
diabetes mellitus at the incipient stage and constant motivation of diabetics 
towards good sugar control may help preventing adverse cardiovascular 
outcomes. 
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LIMITATIONS 
There are various limitations of the study: 
1. Age influences diastolic function. It is a well known fact that as a 
patient ages there is some degree of diastolic dysfunction. 
 
2. Other co morbid illnesses like hypertension and obesity can also 
influence diastolic function. Presence of these risk factors accelerates 
the deterioration of cardiac function. 
 
3. The study excluded those patients with clinical evidence of 
microvascular disease. This microvascular disease can already be 
present in a diabetic patient without the presence of overt symptoms. 
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ANNEXURES 
  
 PROFORMA 
CORRELATION OF HbA1C LEVELS WITH  GRADES  OF 
DIASTOLIC DYSFUNCTION IN ASYMPTOMATIC  
TYPE 2 DIABETIC INDIVIDUALS 
 
Name:               Age:               Sex:   
 
Patient ID:              Contact number:               Occupation: 
 
 
 NAME: 
 
 AGE: 
 
 SEX: 
 
 OP NUMBER: 
 
 TYPE 2 DIABETES - DURATION:                                          
TREATMENT:                                            
OHA/INSULIN: 
 
 PAST HISTORY –  
HYPERTENSION:              CAD:                  PVD:           
 
         STROKE:                            RENAL DISEASE: 
 
PREGNANCY - YES:         NO:          N/A 
 
 CLINICAL EXAMINATION: 
 PALLOR: 
 ICTERUS: 
 CYANOSIS: 
 CLUBBING: 
 GENERALIZED LYMPAHADENOPATHY: 
 PEDAL EDEMA: 
 
 
  
 
 SYSTEMIC EXAMINATION:   
 
CVS:                                               RS: 
        
         CNS:                                               PA:  
 
          INVESTIGATIONS: 
1. FASTING PLASMA GLUCOSE: 
 
2. HbA1C  level 
 
3. Urine routine   -                             Albumin  -                                            
Sugar – 
 
4. ECG: 
 
5. ECHOCARDIOGRAPHY FINDINGS: 
 
TRANSMITRAL INFLOW VELOCITY – 
          E -                      A-                           DT – 
         TISSUE DOPPLER LATERAL ANNULUS VELOCITY –  
          E’ -                     A’-                          E’/A’ 
          LA SIZE – 
          LV END DIASTOLIC PRESSURE – 
          LV SYSTOLIC FUNCTION  - EF – 
          LV MASS 
        
 
  
  
 
 
TURNITIN PLAGIARISM SCREENSHOT
 
 
 
  
 
 
  
 INFORMATION SHEET 
We are conducting a study on “CORRELATION OF HbA1C LEVELS 
WITH GRADES OF DIASTOLIC DYSFUNCTION IN ASYMPTOMATIC 
TYPE 2 DIABETIC INDIVIDUALS” among outpatients visiting Government 
General Hospital, Chennai and for that your sample may be valuable to us.
 
The purpose of this study is to correlate between HbA1C levels with grades 
of diastolic dysfunction in asymptomatic type 2 diabetic individuals . 
 
 We are selecting certain cases and if found eligible, we will be 
using your 4ml of blood sample to be collected in sodium citrate tube to 
perform fasting plasma glucose and HbA1C levels. A routine urine 
examination will also be performed. An ECG and perform a 2D 
echocardiography to determine the cardiac status. 
 The privacy of the patients in the research will be maintained 
throughout the study. In the event of any publication or presentation resulting 
from the research, no personally identifiable information will be shared. 
 Taking part in this study is voluntary. You are free to decide whether 
to participate in this study or to withdraw at any time; your decision will 
not result in any loss of benefits to which you are otherwise entitled. 
 The results of the special study may be intimated to you at the end of 
the study period or during the study if anything is found abnormal which 
may aid in the management or treatment. 
 
Signature of investigator                                       Signature of participant 
Date
   
 CONSENT FORM 
Study Title : CORRELATION OF HbA1C LEVELS WITH         
GRADES  OF DIASTOLIC DYSFUNCTION IN 
ASYMPTOMATIC TYPE 2 DIABETIC 
INDIVIDUALS 
Study Centre :          Rajiv Gandhi Government General Hospital,  
         Chennai. 
Name :  
Age/Sex :  
Identification 
Number 
:  
Patient may check (☑) these boxes 
The details of the study have been provided to me in writing and explained to 
me in my own language ❏ 
I understand that my participation in the study is voluntary and that I am free 
to withdraw at any time without giving reason, without my legal rights 
being affected. ❏ 
I understand that sponsor of the clinical study, others working on the 
sponsor’s behalf, the ethical committee and the regulatory authorities will 
not need my permission to look at my health records, both in respect of 
current study and any further research that may be conducted in relation to 
it, even if I withdraw from the study I agree to this access. However, I 
understand that my identity will not be revealed in any information 
released to third parties or published, unless as required under the law. I 
agree not to restrict the use of any data or results that arise from this study. ❏ 
I agree to take part in the above study and to comply with the instructions 
given during the study and faithfully cooperate with the study team and to 
immediately inform the study staff if I suffer from any deterioration in my 
health or well being or any unexpected or unusual symptoms. ❏ 
I hereby consent to participate in this study. ❏ 
I hereby give permission to undergo complete clinical examination and 
diagnostic tests including hematological and biochemical tests. ❏ 
 
Signature/thumb impression   Signature of Investigator 
of patient 
 
Patient’s Name and Address:      
   
Study Investigator’s Name :Dr. SANDEEP SRINIVAS 
  
  
 
 
 
MASTER CHART 
 
S.No.      NAME    AGE SEX DURATION
OHA(O) / 
INSULIN(I)
HbA1C
LA SIZE 
(mm)
 SYSTOLIC 
FUNCTION 
(EF)%
LV DIASTOLIC 
DYSFUNCTION
LV MASS (gms)
1 JAYAMMA 60 F 96 I 9.6 29 58 GRADE 2 190
2 VEERAPPAN 58 M 156 O+I 13 36 66 GRADE3 300
3 RAVANAMAL 60 F 168 O+I 14.1 37 56 GRADE 3 224
4 SUBRAMANI 55  M 12 O 7.3 25 57.3 NO 98
5 DANIEL 48 M 48 I 11.6 27 60 GRADE 1 234
6 ANBU SELVAN 50 M 24 O 7.5 26 61.7 NO 120
7 SULOCHANA 50 F 72 I 11.6 30 71 GRADE1 166
8 SABASTHIYAMMAL 50 F 180 O+I 14 37.5 64 GRADE 3 220
9 SABINA BEE 49 F 1 O 7.5 25.5 65.4 NO 75
10 EKAMBARAM 48 M 2 O 9 26.7 60 NO 106
11 MUNIYAMMAL 46 F 3 O 8 27 66 NO 110
12 ANANDHAN 50 M 60 I 9 28.2 58 GRADE 1 246
13 RAJIV 55 M 36 O 7 25.6 62 NO 98
14 ANWAR SHERIFF 60 M 240 O+I 10 37 55 GRADE 3 265
15 THANGAVEL 51 M 1 O 8 25.4 64.6 NO 108
15 MUTHU 48 M 1 O 7 25 60 NO 90
16 MUNNUSAMY 47 M 36 I 8.6 27 60 GRADE 1 244
17 ANDRUSE 57 M 180 O+I 12.7 34.5 62 GRADE 2 270
18 SRINIVASAN 51 M 120 I 11.6 33 60 GRADE 2 238
19 SHABEENA 41 F 24 O 8 31.5 66 GRADE 1 170
20 MOORTHY 50 M 60 I 9 30 64 GRADE 1 228
S.No. NAME AGE SEX DURATION
OHA(O) / 
INSULIN(I)
HbAIC LA SIZE (mm)
SYSTOLIC 
FUNCTION 
(EF)%
LV DIASTOLIC 
DYSFUNCTION
LV MASS (gms)
21 JEEVARATHNAM 47 F 36 I 9.6 27.5 70 GRADE 1 165
22 MOHAIYAR 55 M 36 O 7.5 25 6O NO 98
23 MANJITH BASHA 50 M 5 O 7 25.5 64.2 NO 100
24 SUBRAMANIAN 59 M 96 I 10.2 30 65 GRADE 2 265
25 KUMAR 46 M 72 I 8.2 27 60 GRADE 1 246
26 NARAYANAN 54 M 60 O 9 26.5 64.5 GRADE1 230
27 GOVINDARAJ 49 M 120 I+O 9.8 34 60.7 GRADE2 260
28 MOHAN 53 M 84 I 8.8 28 56.8 GRADE1 250
29 SELVI 47 F 8 O 7.9 24.5 67.5 NO 88
30 VANITHA 55 F 60 I 8.8 27 59 GRADE 1 170
31 KAVITHA 59 F 144 I+O 9.5 33 60 GRADE 2 190
32 SURIYA 45 F 12 O 7 25 66 NO 70
33 SANGEETHA 60 F 180 I+O 11 34 62.8 GRADE 2 201
34 CHANDRA 58 F 120 I 12.2 32 68 GRADE 2 196
35 KANDASAMY 54 M 108 I 10.5 29.5 59 GRADE 2 267
36 BALU 60 M 84 I 10.8 27 60.8 GRADE 1 235
37 MADHU 42 F 8 O 7.5 25 57.8 NO 70
38 RAJA 43 M 6 O 7 25.5 70 NO 89
39 RAVI 46 M 48 I 8.4 28 70 GRADE 1 244
40 SANTHOSH 56 F 96 I 9.4 29.7 68 GRADE 2 208
S.NO. NAME AGE SEX DURATION
OHA(O)/ 
INSULIN(I)
HbA1C
LA SIZE 
(mm) 
SYSTOLIC 
FUNCTION 
(EF)%
LV DIASTOLIC 
DYSFUNCTION
LV MASS (gms)
41 SUMITHRA 55 F 72 I 8.2 27 56 GRADE 1 165
42 MOHAN 45 M 60 O 9 26 68 GRADE 1 226
43 VELLAMMAL 47 F 48 O 8.6 26.5 59 GRADE 1 170
44 MANI 56 M 108 I 9.4 30 57.8 GRADE 2 260
45 ARUL 60 M 144 I 10 31.5 60 GRADE 2 275
46 AMUDHA 48 F 1 O 7 25 70 NO 100
47 SURESH 58 M 60 I 8.8 26.7 62 GRADE 1 245
48 THANGAM 59 F 180 I+O 13.5 35 58.4 GRADE 3 212
49 RAMAN 49 M 48 O 9 25 63.5 GRADE 1 230
50 RAGHU 54 M 108 I 9.6 29 68 GRADE 2 266
51 DANDAPANI 60 M 84 I 10.7 28.4 55 GRADE2 270
52 SAMPATH 50 M 72 I 8.3 26 57.4 GRADE1 230
53 LAKSHMI 58 F 96 I 9 27.5 58.2 GRADE 1 180
54 VANITHA 54 F 144 O+I 14 32 64.2 GRADE 3 220
55 RAJESH 53 M 36 O 8 25.6 59 GRADE 1 226
56 SHANMUGAM 48 M 48 O 8.1 26 69 GRADE 1 230
57 MUTHUAMMAL 52 F 108 I 11 27.5 58.6 GRADE 2 198
58 SHANTHI 57 F 132 I 9.9 29 70 GRADE 2 190
59 INDIRA 51 F 48 O 8 26.5 60 GRADE 1 184
60 PONNUSAMY 60 M 180 I+O 13 35 65 GRADE 3 295
S.NO. NAME AGE SEX DURATION
OHA(O)/  
INSULIN(I) 
HbAIC LA SIZE (mm)
SYSTOLIC 
FUNCTION 
(EF)%
LV DIASTOLIC 
DYSFUNCTION
LV MASS 
(gms)
61 VIJAY 54 M 48 O 8.3 26.5 60 GRADE 1 242
62 MEENAKSHI 44 F 36 O 9 26 65 GRADE 1 175
63 VELMANI 59 F 120 I 9.5 30 62 GRADE 2 194
64 SUNDARI 46 F 60 O 8.5 27 70 GRADE 1 165
65 MEENA 53 F 60 I 9.4 27.5 68.3 GRADE 1 171
66 KANNIAMMAL 60 F 120 0+I 10.8 33 56 GRADE 2 195
67 RAMANI 48 F 72 I 11 28 59 GRADE 1 182
68 RANGA 56 M 168 I+O 13.6 35.6 66.4 GRADE 3 298
69 DEVI 49 F 60 O 9.1 27 55 GRADE 1 169
70 BANUMATHI 50 F 24 O 7 25 57.5 NO 76
71 GANGA 60 F 84 I 8 27.5 60.4 GRADE 1 173
72 VANAJA 55 F 108 O+I 9 32 68 GRADE 2 180
73 RAMESH 51 M 48 O 8.9 26.7 70 GRADE 1 234
74 RANI 49 F 60 O 8.3 27 71 GRADE 1 178
75 DAYALAN 54 M 108 I 10.7 30 62.8 GRADE 2 267
76 MARY 57 F 132 I+O 11 32 59.5 GRADE 2 190
77 KAMLA 55 F 60 I 9 27 55.4 GRADE 1 171
78 BHARGAVI 47 F 60 O 9.8 28 68.1 GRADE 1 174
79 SHANTHA 53 F 156 I+O 9.9 30 57 GRADE 2 200
80 SOMU 47 M 48 O 8 26 70 GRADE 1 240
S.NO. NAME AGE SEX DURATION(months)
OHA(O)/  
INSULIN(I) 
HbAIC
LA SIZE 
(mm)
SYSTOLIC 
FUNCTION 
(EF)%
LV DIASTOLIC 
DYSFUNCTION
LV MASS (gms)
81 SARITHA 46 F 60 O 8.8 26 60.2 GRADE 1 170
82 MOHAN 50 M 84 I 9 27.5 59.3 GRADE 1 230
83 MOHANA 52 F 72 I 10 28 55.6 GRADE 1 175
84 KAMALI 60 F 180 O+I 13.8 35.6 57 GRADE 3 225
85 VANILLA 59 F 228 O+I 14.6 36 55 GRADE 3 234
86 PARMILA 51 F 60 I 8 26 68.4 GRADE 1 174
87 THIAGARAJ 45 M 48 O 8.2 25.6 70 GRADE 1 234
88 JEYA 53 F 72 O 8.5 28 69 GRADE 1 172
89 JAYARAMAN 56 M 108 I 9 31 64.4 GRADE 2 272
90 JANAKI 52 F 96 I 10 30.5 69.5 GRADE 2 196
91 LATHA 59 F 120 I+O 10.4 32 58 GRADE 2 208
92 DURAI 52 M 96 I 9.4 29 62 GRADE 1 235
93 DEVAGI 45 F 36 O 9 27.5 72 GRADE 1 169
94 MALA 48 F 60 O 8.2 27 67.2 GRADE 1 178
95 ANAND 60 M 120 I 11.4 30.5 59 GRADE 2 280
96 GOMATHI 55 F 72 I 9.6 27 60 GRADE 1 176
97 CHITHRA 59 F 72 I 10 28 64 GRADE 1 184
98 THANGAM 58 F 96 I+O 10.4 33.5 66.3 GRADE 2 200
99 HARISH 54 M 72 I 9 29 58 GRADE 1 232
100 VANAJA 51 F 60 O 8 28.5 68 GRADE 1 175
